Screener
Sarepta Therapeutics, Inc. SRPT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Litigation contingency charge | 39,000 | — | 39,000 | — |
| Amortization of in-licensed rights | 717 | 667 | 1,408 | 1,268 |
| Total cost and expenses | 387,960 | 495,514 | 760,330 | 1,540,756 |
| Operating income (loss) | 13,291 | 115,577 | 371,724 | (184,809) |
| Other (loss) income, net: | ||||
| Other (expense) income, net | (15,040) | 38,061 | (30,299) | (45,071) |
| (Loss) income before income tax expense (benefit) | (1,749) | 153,638 | 341,425 | (229,880) |
| Income tax expense (benefit) | 3,141 | (43,254) | 15,356 | 20,736 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s operating income?
- Sarepta Therapeutics, Inc. (SRPT) reported operating income of $13.29M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s operating income changed year-over-year?
- Sarepta Therapeutics, Inc.'s operating income decreased by 88.5% year-over-year, from $115.58M to $13.29M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Sarepta Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude